More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

A deeper understanding of the inflammatory processes driving psoriasis and psoriatic arthritis is translating ... which build up into thick, scaly plaques, with a high impact on quality of life ...

We describe 5 patients with moderate to severe chronic plaque psoriasis and 6 patients with psoriatic arthritis that was refractory to conventional systemic and/or topical antipsoriatic treatment ...

Etanercept is one of the most frequently used TNF blockers, and has been approved for use in not only moderate-to-severe plaque psoriasis but also rheumatoid arthritis, polyarticular juvenile ...

Some people will experience comorbidities, or other conditions that coexist with plaque psoriasis. For example, psoriatic arthritis is a type of arthritis that causes stiffness, swelling ...

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Plaque psoriasis is the most common ... Psoriasis and psoriatic arthritis are different diseases, but they are related. Some people may have both at the same time. Whether you're newly diagnosed ...

Rheumatologists’ perceptions of Bimzelx outperform analogue launches of Rinvoq, Skyrizi, and Tremfya in psoriatic arthritis at the three months post-launch mark, according to Spherix Global ...

AbbVie), an IL-23a inhibitor indicated for multiple inflammatory conditions including plaque psoriasis and psoriatic arthritis. In a phase 1 clinical trial, Li and colleagues investigated the ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...